ArticleFrontiers in pharmacology2025

Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma.

Jie Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.